Meeting
2016 ASCO Annual Meeting
Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL).
Authors
Matthew Steven Davids
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Matthew Steven Davids , John F. Gerecitano , Jalaja Potluri , Elisa Cerri , Su Young Kim , Mark Steinberg , Maria Verdugo , Todd A. Busman , Sari H. Enschede , Mehrdad Mobasher , Andrea Best , Monali B Desai , William G. Wierda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT01328626; NCT01889186; NCT02141282
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7528)
DOI
10.1200/JCO.2016.34.15_suppl.7528
Abstract #
7528
Poster Bd #
84
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
First Author: Shaji Kumar
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda
Poster
2022 ASCO Annual Meeting
A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
First Author: Jianyong Li
Poster
2024 ASCO Annual Meeting
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
First Author: Masa Lasica